Journal
/
/
تطوير مثبطات البروتين البروتين التفاعلات استبدال من خلال: تطبيق لتصميم وتطوير غير ATP مثبطات معلمين تنافسي
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
JoVE Journal
Biology
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Biology
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

تطوير مثبطات البروتين البروتين التفاعلات استبدال من خلال: تطبيق لتصميم وتطوير غير ATP مثبطات معلمين تنافسي

English

Automatically Generated

Please note that all translations are automatically generated. Click here for the English version.

11,361 Views

10:33 min

October 26, 2015

DOI:

10:33 min
October 26, 2015

11335 Views
,

Transcript

Automatically generated

The overall goal of the strategy is to generate an effective small molecule drug-like therapeutic through conversion of a peptide inhibitor of a protein protein interaction. This is achieved by establishing a structure activity relationship for the desired peptide protein interaction to understand which parts can be effectively replaced as a second step. Computational chemistry is used to identify viable fragment alternatives for the known peptide determinants, which can then be used to synthesize a library of fragment peptide hybrids.

Next, a library of hybrids is synthesized between these fragments and the truncated peptide in order to generate molecules that can be tested in an in vitro assay to identify molecules that are more drug-like and which recapitulate the activity of the native peptide. The results show more drug-like compounds can be identified using the methodology, and these represent effective starting points for drug discovery of inhibitors of protein protein interactions. So the main advantage of this technique over existing methods like high throughput screening is that protein protein traction are extremely challenging from a drug discovery perspective, and conventional methods do not work well.

The replace strategy involves the stepwise iterative approach and therefore may take longer or is more likely to be effective in the long run. Today I will demonstrate most of the procedures myself with some assistance from my associate, Dr.Sandra Craig, who will set up some of the reactions and procedures. Begin this procedure with validation of the docking protocol, followed by preparation of the receptor binding site and ligands as described in the text protocol to dock the ligands into the Cyclin a groove.

First, select the ligand fit routine from the receptor ligand interactions protocol set to the software, use the receptor and the prepared ligands as input for this protocol. For these runs, select PLP one as the energy grid. The energy grid used by the docking program is the force field for generating ligand receptor interactions and potential poses.

Plp one is peace wise linear potential, which specifically prioritizes hydrogen bonding interactions. Specify that poses be energy minimized and the number of generated poses as 10. Leave all the other parameters at the default values in the first instance.

Display poses in the visualizer program and then sort by descending values of the PLP one score. Use scoring functions such as plp, one to estimate the binding affinity of a docked ligand based on a candidate ligand pose, geometry and non-covalent interaction with the target receptor structure. Visually analyze the top 25%of the scored poses for super impossibility with the known capping group.

Also observe whether the pose has fulfilled interaction filters, which are set to include atom restraints that require intermolecular contacts known to be critical for binding and or are required to position the potential capping group in the correct geometry for amide bond formation. Finally, examine poses for visual complementarity, which is defined as having efficient filling of the binding pocket in a manner that is consistent with known structure activity. Relationships for synthesis of end capping groups, use all commercial starting materials, solvents and reagents and synthesize by conventional synthetic organic chemistry.

Perform thin layer chromatography or TLC on silica gel for monitoring reactions by first dissolving the starting material and reaction mixture in the mobile phase. Then spot the dissolved starting material and reaction mixture on the TLC plate using capillary tubes. Place the TLC plate into the chamber containing the mobile phase.

Once the mobile phase reaches 90%of the TLC plate, remove and air dry the plate. Use UV light to detect the starting material and reaction mixtures as visible spots. Then calculate the RF of each spot, which is the ratio of distance traveled by the spot and the mobile phase.

Next, place the reaction mixture in a separatory funnel and wash it with aqueous acid or base solution as appropriate. Collect the organic solvent and evaporate it in a rotary evaporator before drying. The crude product obtained under a vacuum dissolve 500 milligrams of crude product in three to five milliliters of suitable solvent and added to a silica or RP 18 sample it before drying under air, placed a sample it containing the crude product in silica, reversed phase snap cartridges.

Purify the crude material using automated high performance flash chromatography. Employing a snap 100 gram column with a gradient. Run over 15 column volumes.

Dry the purified product collected in solvent from flash chromatography using a rotary evaporator by evaporating all of the solvent to dryness. Then further dry the product under vacuum to remove all the residual solvents. Perform characterization of the purified product by NMR MS and analytical HPLC as described in the text protocol to synthesize end caped fragment, ligated inhibitory peptides or flips assemble.

End ed peptic compounds through standard solid phase synthesis methods. Activate five equivalents of the C terminal amino acid in 4.4 equivalents of HBTU in two milliliters of DIMETHYLFORMAMIDE or DMF for five minutes. Load the mixture onto rink resin using six equivalents of di isopropyl ethyl amine for one hour at room temperature.

Remove the FM protecting group from the C terminal residue using 20%INE in three milliliters of DMF for 10 minutes. Couple subsequent amino acids step by step at each step. Couple five equivalents of the next amino acid using six equivalents of DI isopropyl, ethyl amine, and 4.4 equivalents of HBTU in two milliliters of DMF for one hour.

At room temperature, apply wash cycles after amino acid coupling and FM D protection steps after peptide assembly. Couple N capping groups using six equivalents of DI isopropyl, ethyl amine, and 4.4 equivalents of HBTU in two milliliters of DMF for one hour at room temperature upon completion of peptide assembly. Treat the reaction mixture with two milliliters of the cleavage mixture overnight to remove side chain protecting groups and Cleve flips from the resin tritrate the resulting product with cold dathyl ether to precipitate and if necessary, concentrate in a rotary evaporator filter the resulting solid and dry under vacuum or freeze dry using a lyophilizer.

At this point, proceed to the fluorescence polarization binding assay as described in the text protocol for determination of competitive binding. The model structure of H-A-K-R-R-L-I-F bound to the cyclone binding groove is shown. The cycling groove consists of two hydrophobic pockets, a larger primary pocket and a smaller secondary pocket, which are bridged by acidic residues depicted in red.

Other important interactions include hydrogen bonding contacts of the peptide backbone and ion pairing interactions of the three basic residues of the peptide here, the binding mode of three five D-C-P-T-R-L-I-F is shown, displayed with hydrogen bonding interactions with side chain atoms of tryptophan two 17 and glutamine 2 54 docked. Poses of three representative and capping groups are shown with each of these compounds possessing hydrogen bonds with the interaction filter atoms of tryptophan two 17 and glutamine 2 54. As depicted by green dashed lines, the fennel subsistent makes Vander wall’s interactions with the secondary hydrophobic pocket.

After watching this video, you’ll have a better understanding on how to perform and apply the replace strategy, converting a known peptide inhibitor into a more drug-like molecule, which inhibits a protein protein traction, and is a starting point for therapeutic development.

Summary

Automatically generated

We describe implementation of the REPLACE strategy for targeting protein-protein interactions. REPLACE is an iterative strategy involving synthetic and computational approaches for the conversion of optimized peptidic inhibitors into drug like molecules.

Related Videos

Read Article